TABLE 3.
Excess Odds Ratio per Gy by Dose Defined by Latency or Age-at-Exposure Windows
| Combined first cancers: | Hodgkin lymphoma, testicular
cancer, cervical cancer |
Hodgkin lymphoma, testicular
cancer |
||
|---|---|---|---|---|
| Cases/controlsb | EOR/Gy (95% CI) | Cases/controlsb | EOR/Gy (95% CI) | |
| Latency windowa (years) | ||||
| 5–9.99 | 62/104 | 0.032 (−0.009, 0.21) | 18/33 | 0.048 (−0.007, 0.35) |
| 10–14.99 | 69/126 | 0.038 (−0.004, 0.16) | 37/77 | 0.028 (−0.008, 0.14) |
| 15–19.99 | 62/135 | 0.078 (0.016, 0.23) | 35/77 | 0.090 (0.014, 0.33) |
| 20–24.99 | 51/97 | 0.52 (0.10, 2.14) | 25/53 | 0.87 (0.13, 9.11) |
| 25–29.99 | 35/74 | 0.34 (0.064, 1.19) | 15/31 | 0.84 (0.11, 9.18) |
| 30–41.83 | 28/57 | 0.35 (0.002, 2.56) | 8/15 | |
| P trendc | 0.0038 | 0.0025 | ||
| P trend adjusted for age at exposurec | 0.018 | 0.015 | ||
| Latency window (years) | ||||
| <20 | 184/357 | 0.052 (0.014, 0.13) | 83/183 | 0.053 (0.012, 0.15) |
| >20 | 111/220 | 0.38 (0.12, 1.04) | 46/93 | 0.77 (0.16, 5.93) |
| P difference | 0.0030 | 0.0013 | ||
| Age at exposure window (years) | ||||
| 10–24.99 | 18/58 | 0.16 (0.027, 0.65) | 18/58 | 0.16 (0.025, 0.67) |
| 25–34.99 | 37/71 | 0.30 (0.091, 0.89) | 32/59 | 0.34 (0.094, 1.13) |
| 35–44.99 | 68/151 | 0.044 (0.000, 0.16) | 40/90 | 0.048 (0.000, 0.20) |
| 45–54.99 | 71/124 | 0.083 (0.004, 0.39) | 24/43 | 0.069 (−0.001, 0.42) |
| 55–64.99 | 61/116 | 0.019d (−0.017,0.17) | 9/24 | 0.017e (−0.017, 0.18) |
| 65–83.67 | 44/61 | 0.58d (0.023, 3.27) | 11/6 | |
| P trendc | 0.077 | 0.069 | ||
| P trend adjusted for latencyc | >0.5 | >0.5 | ||
Note. CI = confidence interval; EOR = excess odds ratio.
Interval between exposure and date of stomach cancer diagnosis or comparable date in controls.
Numbers of cases and controls with nonzero radiation doses in the specified window. Patients could have radiation dose included in more than one window. Thirty-four cases and 104 controls did not have any dose to include in any window, and of these, 28 cases and 78 controls were cervical cancer patients.
For the purpose of evaluating trends with age at exposure and time since exposure, we used the year of the first annual dose that exceeded 5 Gy or the date of the first dose, for patients who never received an annual dose of 5 Gy or more. See Supplementary Materials for additional details on the trend tests.
EOR/Gy for the combined group of ≥55-year window was 0.036 (95% CI: −0.011, 0.22).
EOR/Gy for the combined group of ≥55-year windows. EOR/Gy for the 55–64-year window was 0.013 (95% CI: −0.020, 0.24); EOR/Gy for >65 is infinite (95% CI: 8.5, ∞).